Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Small Molecule CMO/CDMO Market Through 2029?

In the past few years, the small molecule CMO/CDMO market has demonstrated robust growth. Its size is expected to increase from $50.58 billion in 2024 to $54.42 billion in 2025, marking a compound annual growth rate (CAGR) of 7.6%. Several factors have contributed to this upward trend during the historical period including supportive government policies, cost-effective strategies, increasing complexities in drug development, industry amalgamation, and a focus on core expertise.

Expectations indicate robust growth within the small molecule CMO/CDMO market in the coming years. This market is predicted to expand to “$72.9 billion by 2029 with a compound annual growth rate (CAGR) of 7.6%. Growth during this forecast period is linked to expanses in drug pipelines, pharmaceutical operations becoming global, a higher demand for flexible manufacturing, regulatory compliance expertise, and convergence in biopharmaceuticals. Throughout this period, key trends emerging include practices in sustainable and green manufacturing, elevated collaboration and partnerships, tailored medicine and specific therapies, the emergence of both virtual companies and those transitioning from virtual to reality, digital technology integration, and manufacturing facilitating rapid response.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13733&type=smp

What Market Forces Are Driving The Small Molecule CMO/CDMO Sector In 2025 And Beyond?

The boost in pharmaceutical demand is projected to drive the expansion of the small-molecule CMO/CDMO market in the future. The pharmaceutical sector, which comprises the exploration, development, and manufacturing of drugs by public and private organisations, employs small-molecule CMO/CDMO. These services are outsourced to aid in the development, production, and packaging of small-molecule drugs, leading to cost savings, time efficiency, and process optimisation for pharmaceutical firms. For example, the Government of Canada reported in August 2024 that the nation’s pharmaceutical exports increased to 9.59 billion USD (12.79 billion CAD) in 2022 from 10.71 billion CAD in 2021. The sector also witnessed a surge in imports, hitting 30.21 billion CAD from 26.63 billion CAD in 2021. Hence, the escalating need for pharmaceuticals is acting as a catalyst for the growth of the small-molecule CMO/CDMO market.

The small molecule cmo/cdmo market covered in this report is segmented –

1) By Product: Small Molecule Drug Product, Small Molecule API

2) By Stage Type: Clinical, Commercial, Preclinical

3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Cardiovascular Disease, Respiratory Disorders, Metabolic Disorders, Other Therapeutics

4) By Application: Cardiovascular, Oncology, Diabetes, Immunological Disorders

Subsegments:

1) By Small Molecule Drug Product: Solid Dosage Forms (Tablets, Capsules), Liquid Dosage Forms (Injectables, Solutions), Topical Dosage Forms

2) By Small Molecule API (Active Pharmaceutical Ingredient): Generic APIs, Branded APIs, Custom Synthesis APIs

What Trends Are Currently Influencing Growth In The Small Molecule CMO/CDMO Market?

Key players in the small-molecule CMO/CDMO market are turning their attention to ground-breaking technologies such as the cutting-edge small-molecule platform based in Shanghai to enhance their CDMO offerings. This innovative platform signifies the pinnacle of technological breakthroughs tailored for the development and production of small-molecule medicines, promising safer, more potent, and more efficiently manufactured pharmaceutical products. For instance, in June 2023, Porton Pharma Solutions Ltd., a Chinese pharmaceutical company, inaugurated its avant-garde small-molecule platform in Shanghai, thereby escalating its CDMO services. This platform exemplifies an all-encompassing strategy, merging the latest technologies and systems to enrich the entire lifecycle of small molecule pharmaceuticals. Key features include one-stop-shop solutions, a comprehensive platform, provision of flexibility and availability, and digitization.

Which Firms Are Considered Leaders In The Small Molecule CMO/CDMO Market Space?

Major companies operating in the small molecule CMO/CDMO market report are Patheon NV (Thermo Fisher Scientific), GlaxoSmithKline, Johnson Matthey PLC, Lonza Group Ltd., WuXi AppTec, Catalent Inc., Aurobindo Pharma, Fareva, Aesica Pharmaceuticals Limited, Siegfried holdings AG, Recipharm AB, Jubilant Life Sciences Limited, Almac Group, Piramal Pharma Solutions, Oxford Chemicals Inc., Syngene International Limited, Novasep, Pfizer CentreOne, GVK Biosciences, ChemPartner, Avid Bioservices Inc., Dishman Carbogen Amcis Ltd., ProChem Inc., Metrics Contract Services

https://www.thebusinessresearchcompany.com/report/small-molecule-cmo-or-cdmo-global-market-report

What Role Do Regional Policies And Investments Play In Small Molecule CMO/CDMO Market Expansion?

North America was the largest region in the small molecule CMO/CDMO market in 2024. The regions covered in the small molecule CMO/CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13733&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model